1. Home
  2. TNXP vs CXDO Comparison

TNXP vs CXDO Comparison

Compare TNXP & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$11.09

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

CXDO

Crexendo Inc.

HOLD

Current Price

$7.61

Market Cap

223.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
CXDO
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
223.1M
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
TNXP
CXDO
Price
$11.09
$7.61
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.20
AVG Volume (30 Days)
430.5K
673.7K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
166.67
EPS
N/A
0.02
Revenue
$13,107,000.00
$68,167,000.00
Revenue This Year
$558.11
$45.26
Revenue Next Year
$38.29
$13.31
P/E Ratio
N/A
$451.50
Revenue Growth
29.85
12.05
52 Week Low
$11.21
$5.13
52 Week High
$69.65
$11.23

Technical Indicators

Market Signals
Indicator
TNXP
CXDO
Relative Strength Index (RSI) 37.57 34.80
Support Level N/A $6.04
Resistance Level $14.85 N/A
Average True Range (ATR) 0.91 0.69
MACD -0.24 -0.29
Stochastic Oscillator 3.39 2.14

Price Performance

Historical Comparison
TNXP
CXDO

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.

Share on Social Networks: